Skip to content Skip to footer
Exclusive_Kenneth-Sake_2025

Exclusive: Kenneth Sake from Blueprint Medicines in an Enlightening Conversation with PharmaShots

Highlights:  Systemic mastocytosis (SM) is a rare disease caused by the abnormal accumulation of mast cells – a key part of the body’s immune system People with SM face potentially debilitating symptoms, such as skin lesions, diarrhoea, bone pain, fatigue and anaphylaxis, which can present challenges across various aspects of patients’ lives For more than…

Read more

VIEWPOINTS_Nicolas Paquette-Lamontagne_2023

Nicolas Paquette-Lamontagne, VP, Medical Affairs at Blueprint Medicines Shares his Views on Clinical Data of Ayvakit for Patients with Systemic Mastocytosis

Shots:  Nicolas discussed about Systemic Mastocytosis as a disease and highlighted its epidemiology & other details. He also spoke about the clinical data of avapritinib presented at the ASH’22 Annual Meeting     Nicolas also shared the key findings from the PATHFINDER and EXPLORER trial evaluating avapritinib and the rationale behind conducting two different trials  This interview…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]